Hi Zazarre -
Sorry I did not get back to you sooner .....
(a) I own around 35,000 shares.
(b) Everyone is free to speculate about NTI's
need to do another placement.
my speculation is that they are $15 million
short and therefore will have to do one.
I don't want to spend energy defending this *feeling*
but I threw these numbers out on Yahoo some
weeks ago .... they are a road map and probably
better estimates could be made ....
NOTE:
I would NOT recommend NTII to anyone ...
too many loose ends ...
Yahoo post
==========
Cash (all accounts)
(a) Beginning Balance 9/30/04
************
ON HAND
************
$16,581
Plus
************
INFLOWS
************
(b) Estimated Inflows for 5
Quarters
Royalties:
(1) This quarter $765
(2) Jan-Mar-05 $1,000
(3) Apl-Jun-05 $1,100
(4) Jul-Sep-05 $1,200
(5) Oct-Dec-05 $1,300
------------------------
Total $5,365
-----------------------
equals
************
(c)Total Available Cash
************
$21,946 (a) + (b)
less
************
OUTFLOWS
************
(d)Estimated OutFlows for 5
Quarters
(1) This quarter $2,000
(2) Jan-Mar-05 $2,500
(3) Apl-Jun-05 $2,700
(4) Jul-Sep-05 $3,000
(5) Oct-Dec-05 $3,300
------------------------
Total $13,500
-----------------------
************
NET CASH
************
(e) AT Sept 30 - 2005
---------------------
$8,446 (c) minus (d)
=====================
=================
end Yahoo post
=================
Error:(e) Should really say Dec 31, 2005
One of the weird things on the horizon
maybe as follows:
(1) Xerecept works - but
(a) No way to finance a sales team to sell it, and,
(b) sales effort reduced by limited product need
i.e. used only in chronic because of the (anticipated
huge) cost difference between Xerecept vs Dex_I_cant
spell_the_rest current steriod in use.
Finally, it goes without saying that I hope
I am dead wrong about all the stuff above,
and time will tell.
Whether I stay here or not largely depends on
the upcoming results of the DN P2 trial.
regards,
John |
